BC
ALNY icon

Bridgefront Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bridgefront Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,998
Closed -$486K – 517
2024
Q2 		$486K Buy
1,998
+129
+7% +$20.4K 0.2% 167
2024
Q1 		$279K Buy
+1,869
New +$312K 0.21% 207
2022
Q4 		– Sell
-1,921
Closed -$385K – 357
2022
Q3 		$385K Buy
+1,921
New +$366K 0.39% 78

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bridgefront Capital's ALNY Position: Q3 2024 in Review

Bridgefront Capital sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2024, closing a stake of 1,998 shares — an estimated $486K sold.

Bridgefront Capital first reported a position in ALNY in Q3 2022 and held it in 3 quarters. The position peaked at $486K in Q2 2024. 567 funds tracked by Wall St. Rank hold ALNY as of Q3 2024.

  • Bridgefront Capital reported no remaining Alnylam Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Bridgefront Capital sold 1,998 Alnylam Pharmaceuticals shares in Q3 2024, an estimated $486K.
  • Bridgefront Capital first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 3 quarters.
  • Bridgefront Capital's Alnylam Pharmaceuticals position peaked at $486K in Q2 2024.
  • 567 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2024.

Based on Bridgefront Capital's 13F filing for Q3 2024, filed 14 Nov 2024.